Skip to main content

Advertisement

Table 1 Characteristics of GIST patients in test and validation cohort without imatinib adjuvant therapy

From: Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome

  Test cohort (n = 212) Validation cohort (n = 158) Pvalue
Age (years)    
≤ 50 36 (17.0%) 37 (23.4%) 0.124
> 50 176 (83.0%) 121 (76.6%)  
Gender    
Male 114 (53.8%) 85 (53.8%) 0.996
Female 98 (46.2%) 73 (46.2%)  
Tumor site    
Stomach 129 (60.8%) 82 (51.9%) 0.094
Small bowel 48 (22.6%) 54 (34.2%)  
Colon 10 (4.7%) 8 (5.1%)  
Others 25 (11.9%) 14 (8.9%)  
Tumor size (cm)    
≤ 2.0 20 (9.4%) 16 (10.1%) 0.408
2.1-5.0 100 (47.2%) 61 (38.6%)  
5.1-10.0 59 (27.8%) 54 (34.2%)  
> 10.0 33 (15.6%) 27 (17.1%)  
Mitoses per 50 HPFs    
≤ 5 175 (82.5%) 118 (74.7%) 0.078
6-10 23 (10.8%) 19 (12.0%)  
> 10 14 (6.7%) 21 (13.3%)  
Modified NIH criteria    
Very low risk 18 (8.5%) 14 (8.9%) 0.087
Low risk 96 (45.3%) 56 (35.4%)  
Intermediate risk 38 (17.9%) 24 (15.2%)  
High risk 60 (28.3%) 64 (40.5%)  
Serosal invasion    
Yes 23 (10.8%) 20 (12.7%) 0.591
No 189 (89.2%) 138 (87.3%)